Melioidosis—a bacterial infection that causes fever, pneumonia, and sepsis—presents two enormous challenges for infectious ...

A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...

A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.The research ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung ...

Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an ...

Prof. Daugaard will deliver a podium presentation highlighting Rakovina Therapeutics’ research and the Company’s product development pipeline, followed by examples of various model systems used by the ...

The myeloMATCH precision medicine trials (NCT05564390), funded by the NCI, were officially launched on May 16, 2024.

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia ...

The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...